Literature DB >> 12369232

Cost-benefit analysis of a new HEDIS performance measure for pneumococcal vaccination.

Faruque Ahmed1, Elamin E Elbasha, Betsy L Thompson, Jeffrey R Harris, Vishnu-Priya Sneller.   

Abstract

OBJECTIVES: Measurement of the quality of care provided by managed care organizations (MCOs) has achieved national prominence, though there is controversy regarding its value. This article assesses the economic implications of a new Health Plan Employer Data and Information Set (HEDIS) measure for pneumococcal vaccination.
METHODS: A Markov decision model, with Monte Carlo simulations, was utilized to conduct a cost-benefit analysis of annual HEDIS-associated interventions, which were repeated for 5 consecutive years, in an average Medicare MCO, using a societal perspective and a 3% annual discount rate.
RESULTS: Compared with the status quo, the HEDIS intervention will be cost saving 99.8% of the time, with an average net savings of $3.80 per enrollee (95% probability interval: $0.73-$6.87).
CONCLUSIONS: The new HEDIS measure will save societal dollars. This type of analysis is essential if performance measurement is to become a legitimate part of our health care landscape.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369232     DOI: 10.1177/027298902237711

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  3 in total

1.  Clinical improvement associated with conformance to HEDIS-based depression care.

Authors:  Kathryn Rost; L Miriam Dickinson; John Fortney; John Westfall; Richard C Hermann
Journal:  Ment Health Serv Res       Date:  2005-06

2.  Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults.

Authors:  J H Flory; M Joffe; N O Fishman; P H Edelstein; J P Metlay
Journal:  Epidemiol Infect       Date:  2008-10-17       Impact factor: 2.451

Review 3.  Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jennifer Murphy Morgan; Adesola A Pitan; John M Clymer
Journal:  Am J Prev Med       Date:  2016-02-01       Impact factor: 5.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.